Table Graph
      published meta-analysis   sensitivity analysis   studies

placebo in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsC3PO, 2020 (REV) 0.20 [0.02; 1.72] CoV-Early (Gharbharan), 2022 (REV) 0.99 [0.06; 15.94] 0.36[0.07; 2.00]C3PO, 2020 (REV), CoV-Early (Gharbharan), 2022 (REV)20%927moderatenot evaluable deathsdetailed resultsC3PO, 2020 (REV) 0.20 [0.02; 1.72] CONV-ERT, 2021 (REV) 5.00 [0.25; 101.73] CoV-Early (Gharbharan), 2022 (REV) 0.99 [0.06; 15.94] 0.78[0.12; 4.97]C3PO, 2020 (REV), CONV-ERT, 2021 (REV), CoV-Early (Gharbharan), 2022 (REV)333%1,275lownot evaluable hospitalization or deathdetailed resultsC3PO, 2020 (REV) 1.09 [0.75; 1.59] 1.09[0.75; 1.59]C3PO, 2020 (REV)10%511NAnot evaluable hospitalizationdetailed resultsC3PO, 2020 (REV) 1.14 [0.75; 1.75] CONV-ERT, 2021 (REV) 0.95 [0.71; 1.28] CoV-Early (Gharbharan), 2022 (REV) 1.64 [0.75; 3.59] 1.05[0.84; 1.33]C3PO, 2020 (REV), CONV-ERT, 2021 (REV), CoV-Early (Gharbharan), 2022 (REV)30%1,275lownot evaluable mechanical ventilationdetailed resultsC3PO, 2020 (REV) 0.67 [0.11; 4.04] 0.67[0.11; 4.04]C3PO, 2020 (REV)10%498NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-06-09 02:05 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 650 - roots T: 650

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons